Journal of magnetic resonance imaging : JMRI
-
J Magn Reson Imaging · Feb 2018
Multicenter StudyAssociation of diabetes mellitus and biochemical knee cartilage composition assessed by T2 relaxation time measurements: Data from the osteoarthritis initiative.
To investigate the association of the presence and severity of diabetes mellitus (DM) with articular cartilage composition, using magnetic resonance imaging (MRI)-based T2 relaxation time measurements, and structural knee abnormalities. ⋯ 2 Technical Efficacy: 5 J. Magn. Reson. Imaging 2018;47:380-390.
-
J Magn Reson Imaging · Jan 2018
Multicenter Study Comparative StudyComparison of arterial spin labeling registration strategies in the multi-center GENetic frontotemporal dementia initiative (GENFI).
To compare registration strategies to align arterial spin labeling (ASL) with 3D T1-weighted (T1w) images, with the goal of reducing the between-subject variability of cerebral blood flow (CBF) images. ⋯ 1 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2018;47:131-140.
-
J Magn Reson Imaging · Jul 2017
Multicenter Study Clinical TrialRadiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study.
To evaluate in a multi-institutional study whether radiomic features useful for prostate cancer (PCa) detection from 3 Tesla (T) multi-parametric MRI (mpMRI) in the transition zone (TZ) differ from those in the peripheral zone (PZ). ⋯ 3 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:184-193.
-
J Magn Reson Imaging · Dec 2015
Multicenter StudyWhole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study.
To assess the performance of whole-body MRI including diffusion-weighted imaging (whole-body MRI-DWI) for the detection of residual disease after completion of treatment in lymphoma patients. ⋯ Our initial results suggest that visual whole-body MRI-DWI analysis has a very good sensitivity for detecting viable residual lesions after completion of therapy but lacks specificity. ADC measurements could potentially increase the specificity of whole-body MRI.
-
J Magn Reson Imaging · Mar 2015
Multicenter StudyPhase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gadobutrol is a 1.0 M macrocyclic magnetic resonance imaging (MRI) contrast agent. A study was performed to evaluate the efficacy and safety of gadobutrol-enhanced versus unenhanced imaging for central nervous system (CNS) lesion visualization and detection. ⋯ Gadobutrol 1.0M is an effective and well-tolerated contrast agent for CNS MRI.